Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss?
These preliminary results suggest that bortezomib shows negligible favorable effects on cancer-associated weight loss in patients with metastatic pancreatic cancer. We conclude that further study of bortezomib specifically in this setting and for this indication is not warranted.
Collectively, our data demonstrate that the additional renoprotective effects of angiotensin II blockade by losartan are associated with upregulation of megalin in the renal proximal tubule of SHRs. Moreover, it strengthens the view that tubular dysfunction may represent an important contributing mechanism underlying proteinuria in hypertension.